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Abstract 
Ambulatory blood pressure monitoring (ABPM) is being used increasingly for the evaluation of antihypertensive 
agents in clinical trials. In this brief review several aspects of ABPM are discussed. In particular, attention is paid to 
the extent to which AE3PM is subject to a placebo response and the extent to which the sample size of the study 
population can be reduced with this type of measurement. In addition, some remarks are made with regard to how 
selection of patients with this methodology can be improved and how it may be used as a tool to evaluate the 
duration of action of antihypertensive agents. Finally, some potential disadvantages of ABPM as compared to 
conventional clinic blood pressure measurements are discussed. 
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1. Introduction 
Although the place of ambulatory blood pres- 
sure monitoring (ABPM) for the management of 
the individual hypertensive patient has still to be 
decided, this methodology has obtained a defini- 
tive place in the assessment of the blood-pres- 
sure-lowering effect of antihypertensive drugs in 
clinical trials. 
Compared to convential clinic blood pressure 
measurements AESPM appears to have a number 
of favourable aspects and relatively few disadvan- 
tages (Table 1). 
* Tel. (OlO)-4633762; Fax (OlO)-4634531. 
In this paper we will focus on the question of 
the extent to which AE3PM is subject to a placebo 
response and how it may influence the sample 
size of the study population, whereas the other 
Table 1 
Advantages and diasadvantages of ambulatory blood pressure 
monitoring in clinical trials with antihypertensive drugs 
Advantages Disadvantages 
Reduction of placebo effect Inconvenience for 
the patient 
Reduction of sample size Uncontrolled conditions 
Evaluation of duration of effect 
Evaluation of effect on diurnal 
rhythm of blood pressure 
Improved patient selection 
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points summarized in Table 1 will be discussed 
only briefly. 
2. Evaluation of duration of effect 
Most of the classes of antihypertensive agents 
currently used have a similar effect on the day 
and night blood pressure, thereby leaving the 
normally occurring diurnal variation of blood 
pressure undisturbed. 
For the evaluation of the duration of effect of 
an antihypertensive compound it is necessary to 
perform blood pressure measurements at re- 
peated intervals. Obviously this can be done by 
means of convential clinic blood pressure mea- 
surements; however, this is a laborious procedure 
and in addition it has the disadvantage that mea- 
surements can only be performed in a clinical 
setting while the patient is at rest. With ABPM a 
large number of blood pressure measurements 
can be taken over an extended period of time 
with the patient active at home or at work. This 
has the advantage that information about the 
duration of the blood-pressure-lowering effect can 
be obtained under more real-life conditions. 
The centrally acting sympathicolytic agent LY- 
methyldopa, which effectively lowers blood pres- 
sure during the day, has been shown to have little 
effect on nocturnal blood pressure [27 and similar 
observations have been made with the combined 
(Y- and P-adrenoceptor antagonist, labetolol [3]. 
From these observations it might be concluded 
that an increase in the activity of the sympathetic 
nervous system during the day contributes consid- 
erably to the higher level of blood pressure over 
this period. 
As part of the evaluation of a new antihyper- 
tensive agent it is customary to compare the 
effect at the end of the dose-interval, the trough 
effect, with the maximal or peak antihypertensive 
effect. Calculation of the trough to peak ratio 
may be helpful by determining the dose interval 
of the antihypertensive agent. For example, for 
an antihypertensive agent with a claimed dura- 
tion of action of 24 h the trough antihypertensive 
effect at the end of the dose interval should be at 
least 50% of the peak effect. In order to obtain 
approval for registration, the Food and Drug 
Aministration (FDA) in the United States re- 
quires information about the trough and peak 
effects of the antihypertensive agent under con- 
sideration [ 11. 
The effect of antihypertensive agents on the 
diurnal blood pressure profile is not merely of 
academic interest, but may be important in the 
light of observations that a number of cardiovas- 
cular morbid events, such as myocardial infarc- 
tion and ischaemia as well as thrombotic and 
haemorrhagic strokes, exhibit a diurnal rhythm as 
well [4-61. 
4. Selection of patients 
3. Evaluation of the effect on the diurnal rhythm 
of blood pressure 
In almost all reported clinical trials with anti- 
hypertensive drugs convential blood pressure 
measurements have been used as an entry-crite- 
rion for the selection of patients. A consequence 
of this method of selection is that apart from 
subjects with genuine hypertension a number of 
subjects with so-called white-coat hypertension 
will be included as well. The effectiveness of 
antihypertensive agents in white-coat hyperten- 
sives is minimal or absent, as has been demon- 
strated for calcium entry blockers [7,8]. Inclusion 
of this category of subjects will therefore lead to a 
dilution of the antihypertensive effect of the agent 
studied. 
In both normotensive and hypertensive sub- Furthermore, administration of antihyperten- 
jects blood pressure shows a diurnal rhythm with sive agents to subjects who are not truly hyper- 
a markedly lower blood pressure during the night tensive may be associated with more side-effects. 
than during the day. By means of ABPM it is It may be argued therefore that, instead of the 
possible to evaluate the effect of antihypertensive convential clinic blood pressure measurements, 
agents on this diurnal blood pressure rhythm. ABPM should be used as an entry-criterion to 
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select patients for clinical trials with antihyper- 
tensive agents. 
5. Reduction of placebo effect 
According to Wolf a placebo response may be 
defined as any effect attributable to a pill, potion 
or procedure, but not its pharmacodynamic or 
specific properties [9]. The susceptibility of con- 
vential clinic blood pressure measurements to a 
placebo has been well established in some large 
intervention trials. One example is the Australian 
Trial in Mild Hypertension [lo]. Subjects were 
eligible to enter this trial if their diastolic blood 
pressure during a run-in period of 4 weeks varied 
between 95 and 109 mmHg (average of 6 mea- 
surements). At the end of the run-in period 1408 
subjects were randomized for placebo. After an 
observation period of 3 years it appeared that 669 
of these subjects, i.e. almost 50%, had a diastolic 
blood pressure below 95 mmHg. 
The way in which placebo lowers blood pres- 
sure is not precisely known. Habituation to the 
environment, to the procedure of blood pressure 
measurement and to the doctor or nurse, who 
measures the blood pressure, is probably the most 
important factor. Regression to the mean may 
also play a role. For an antihypertensive drug 
trial subjects are selected on the basis of an 
elevated blood pressure. On mere statistical 
grounds it can be expected that in a proportion of 
these subjects this abnormality diminishes with 
time. The inherent wide variability of blood pres- 
sure, of which the clinic blood pressure measure- 
ment is only a momentary estimate, as well as the 
expectations of the patient or physician with re- 
spect to treatment are factors which may also 
contribute to the placebo response. 
The effect of placebo on ABPM has been 
investigated in several studies (Table 2). In a 
relatively large number of patients the Rembler @ 
monitor has been used for the measurement of 
blood pressure. The Rembler@ monitor is a non- 
automatic recorder. The cuff has to be inflated by 
the patient himself, so that only day-time values 
of blood pressure can be obtained. When the 
day-time blood pressure values of the ambulatory 
Table 2 
Studies comparing effect of placebo on clinic and ambulatory 
blood pressure measurements 
Refer- No. of Methodology of blood 
ence no. patients pressure monitoring 
11 20 Invasive (Oxford technique) 
12 66 Non-invasive (RembIer @ monitor) 
13 42 Non-invasive (Copal@ monitor) 
14 10 Non-invasive (Spacelabs@ monitor) 
recordings performed in the studies summarized 
in Table 2 were compared with untreated clinic 
blood pressures it appeared that the latter mea- 
surements were considerably higher (Fig. 1). The 
responses of clinic and ambulatory blood pres- 
sure measurements to placebo, given for 3-6 
weeks, are depicted in Fig. 2. In response to 
placebo the decrements in clinic systolic and dias- 
tolic blood pressure were respectively 9.0 and 4.5 
mmHg. For the ambulatory measurements these 
decrements were considerably smaller: respec- 
tively 3.0 mmHg systolic and 1.8 mmHg diastolic. 
The small effect of placebo on ABPM is mainly 
present during the initial hours of the 24-h 
recording as has been shown by Mutti et al. [15]. 
On the basis of the above-mentioned data it 
can be concluded that ABPM, at least in short- 
mmHg 180- 
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Fig. 1. Untreated clinic and daytime ambulatory blood pres- 
sures in 130 patients. Data are derived from the studies 
mentioned in Table 2. 
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Fig. 2. Responses of clinic and daytime ambulatory systolic 
and diastolic blood pressure to placebo in 130 patients. Open 
bars = clinic blood pressure; hatched bars = daytime ambula- 
tory blood pressure. 
term studies, is only minimally affected by 
placebo. This almost absent effect of placebo on 
ABPM provides strong evidence that the placebo 
effect on clinic blood pressure is mainly caused 
by a decrease of the so-called white-coat effect or 
pressor response and not by a real sustained 
reduction of blood pressure. 
6. Effects on sample size of the study 
When the effectiveness of antihypertensive 
therapy is investigated, it has to be taken into 
consideration that blood pressure is a highly vari- 
able parameter from one occasion to another. 
Hills and Armitage have outlined the require- 
ments for estimating the sample size for a cross- 
over or parallel group trial [16]. Three factors are 
predetermined by the investigator. These factors 
are: (1) the power or precision of the study (usu- 
ally set at 80 or 90%), the power being the 
probability of obtaining a significant result if there 
is a true difference between the treatments; (2) 
the level of significance acceptable (usually set at 
p < 0.05); and (3) the minimum difference be- 
tween treatments to be detected. Given these 
requirements, which are independent of the 
methodology of blood pressure measurement, the 
determinant of the sample size will be the vari- 
ability or the repeatability of the blood pressure 
measurement itself. It is clear that if the variabil- 
ity of the blood pressure measurement is high, it 
becomes more difficult to detect any effect of 
treatment and that a larger sample size has to be 
studied. 
For blood pressure it appears that the repeata- 
bility can be markedly improved by increasing the 
number of measurements [17,18]. In a recent 
study we have measured blood pressure by con- 
vential standard mercury sphygmomanometry and 
with an oscillometric device for ABPM (Space- 
labs 90207 blood pressure monitor) in 42 hyper- 
tensive patients on two occasions, 1 week apart, 
while the subjects were taking placebo. The clinic 
blood pressure measurements were performed in 
triplicate by an experienced investigator with the 
subject in a supine position for 20 min. The three 
values obtained on each occasion were averaged. 
ABPM was measured 4 times per hour during the 
day and 2 times per hour during the night. From 
these recordings 24-h averages of systolic and 
diastolic blood pressure were calculated. Between 
the first and second occasion the mean difference 
in clinic systolic and diastolic blood pressure was 
respectively 8.3 and 5.2 mmHg, with correspond- 
ing standard deviations of these differences of 
13.4 and 7.3 mmHg. For 24-h ABPM the mean 
difference in systolic and diastolic blood pressure 
between the first and second occasion was re- 
spectively 2.3 and 2.2 mmHg, with corresponding 
standard deviations of 6.3 and 4.7 mmHg (Fig. 3). 
Thus, compared to the clinic blood pressure mea- 
surements, the standard deviation of the differ- 
ences (SDD) between the repeated 24-h ambula- 
tory measurements was almost two-fold smaller. 
This reduced variability has important conse- 
quences for the number of patients to be studied 
in clinical trials. For a cross-over trial the number 
of patients to be studied can be calculated from 
the formula: 
n = 10 X SDD*/Difference=, 
where n = the number of patients, SDD = stan- 
dard deviation of differences between measure- 
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ments and Difference = predetermined treatment 
effect to be detected. Thus, for a similar treat- 
ment effect to be detected a two-fold reduction in 
variability means a four-fold reduction in the 
number of patients to be studied. Generally spo- 
ken, to halve the standard deviation of differ- 
ences between trial readings will double the pre- 
cision or power of the trial or allow a four-fold 
reduction in the number of patients to obtain an 
accurate result. 
One remark has to be made. Although 24-h 
average blood pressures obtained by ABPM are 
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much more reproducible than clinic blood pres- 
sure measurements, the reproducibility of hourly 
blood pressure averages (mean of 2-4 values) 
obtained by ABPM appears to be quite variable. 
In a group of 15 subjects Trazzi et al. reported 
that SDD values of hourly averages ranged from 
7 to 18 mmHg for systolic and from 6 to 13 
mmHg for diastolic blood pressure 1193. Obvi- 
ously, this limited hourly reproducibility has im- 
portant consequences for sample size calculations 
if one is interested in the duration of action of 
antihypertensive drugs. 
Difference: 2.3 mmHg 
SDD : 6.3 mmHg 
- . . l . 
Difference: 2.2 mmfig 
SDD :4.7 mmtig 
.‘“.o 80 90 100 
Ambulatory diastolic BP average of two occasions (mmHg) 
Fig. 3. Variability of repeated clinic and 24-h ambulatory pressure measurements. On both occasions all subjects were on placebo. 
The time interval between the two occasions was 1 week. SDD denotes standard deviation of differences. 
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7. Disadvantages of ambulatory blood pressure 
recording 
The most important disadvantage of ABPM is 
that the environmental conditions of blood pres- 
sure measurement as compared to clinic blood 
pressure measurements are less strictly stand- 
ardized. Especially in a clinical trial all efforts 
should be made to standardize the conditions of 
measurements as much as possible. This can best 
be achieved by performing the measurements on 
similar days of the week and by introducing timed 
periods of controlled activity like walking, sitting, 
watching television etc. It is also important that 
on the occasions when blood pressure is mea- 
sured, patients have fixed times for their nightrest 
and meals. 
A second disadvantage of ABPM is that the 
number of recordings that can be performed in 
one and the same patient is limited. Most pa- 
tients do not feel very comfortable when they are 
equipped with blood pressure monitors that mea- 
sure their blood pressure at frequent intervals 
both during the day and during the night. In a 
relatively large proportion of patients, ABPM has 
a negative influence on the quality of sleep. 
Whether this disturbance of sleep has an influ- 
ence on the blood pressure level itself remains 
uncertain. Parati et al. found that the average 
overnight reduction in intra-arterial blood pres- 
sure during sleep was preserved during simulta- 
neous recordings with an ambulatory blood pres- 
sure monitor [20]. In contrast, in a recent study 
Davies et al. found that blood pressure measure- 
ments during sleep with an ambulatory blood 
pressure monitor cause a variable rise in simulta- 
neously recorded beat to beat systolic and dias- 
tolic blood pressure and, additionally, that these 
measurements are often associated with elec- 
troencephalographic arousal from sleep 1211. 
8. Conclusion 
For the evaluation of the effectiveness and 
duration of action of antihypertensive drugs 
ABPM offers many advantages when compared 
with convential clinic blood pressure measure- 
ments. The almost complete elimination of the 
placebo response and the much better repeatabil- 
ity of ABPM allow smaller numbers of patients to 
be studied. This reduces costs and, more impor- 
tantly, improves safety, because fewer patients 
have to be exposed to a new antihypertensive 
agent in the initial phase of clinical studies. 
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